Morgan Stanley Maintains Overweight on Nurix Therapeutics, Raises Price Target to $38
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Terence Flynn maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and raises the price target from $36 to $38.
Morgan Stanley analyst Terence Flynn maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and raises the price target from $36 to $38.